Fiona R. Rodepeter
Papers
1
Total Citations
40
H-Index
1
About
Dr. Fiona R. Rodepeter is a translational researcher whose work sits at the intersection of gynecologic oncology and precision molecular diagnostics. Her primary research focus is on homologous recombination deficiency (HRD) as a critical biomarker in ovarian carcinoma, where she has made significant contributions to understanding how genomic instability can guide targeted therapy strategies. In her landmark 2022 study, which has already garnered 40 citations, Dr. Rodepeter led a comprehensive evaluation of HRD in a real-world cohort of 514 ovarian carcinoma samples. By employing next-generation sequencing of DNA libraries that included BRCA1/BRCA2 alongside 26,523 single-nucleotide polymorphisms, she demonstrated the feasibility and clinical utility of HRD testing outside of controlled trial settings. This work has been instrumental in bridging the gap between laboratory-based genomic assays and routine clinical decision-making for ovarian cancer patients. Dr. Rodepeter’s research provides a robust framework for identifying patients most likely to benefit from PARP inhibitor therapies, directly impacting treatment paradigms and highlighting the importance of real-world evidence in precision oncology.
Research Focus
Key Achievements
Top Papers
- 1